CDTRP 2023 Research Innovation Grant Competition Results
CDTRP is thrilled to announce the results of the CDTRP 2023 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.
We would like to extend our warmest congratulations to Dr. Blayne Amir Sayed and his team for being awarded the CDTRP SickKids Research Innovation Grant. We wish them all the best as they embark on their innovative project!
“Congratulations to Dr. Sayed; the SickKids Transplant and Regenerative Medicine Centre is pleased to collaborate with the CDTRP to support this important research investigating how to reduce proinflammatory damage to limit liver ischemia-reperfusion injury. We look forward to hearing the results of this work and its potential impact in minimizing tissue injury during liver transplantation.”
– Dr. Upton Allen, Interim Medical Director, SickKids Transplant and Regenerative Medicine Centre
CDTRP SickKids Research Innovation Grant: Dr. Blayne Amir Sayed
Reduction of proinflammatory damage to limit liver ischemia-reperfusion injury
- Main affiliation: The Hospital for Sick Children Research Institute
- Theme 3 – Engineer and Allocate Better Grafts
Only fifty percent of Canadians on the waitlist i n 2020 for liver transplantation received a transplant that year. This trend of insufficient number of organs available for the number of patients in need is projected to worsen. However, we are limited by the number of suitable livers that are available to transplant. To increase the number of usable livers, we need to have the ability to salvage and improve the function of more marginal organs. We have identified a novel strategy for inhibiting an essential protein involved in cell rupture induced by stress similar to what occurs during liver transplantation. This targeted therapy prevents a significant proportion of cellular and tissue injury in an animal model of liver injury. Interestingly, we still see an independent inflammatory pathway occurring despite this successful inhibition. We suspect that a more complete liver protection could be obtained by utilizing a combinatorial approach: inhibiting cell rupture AND the upstream inflammatory mediators. Our objective is to investigate this approach using a mouse model of liver injury that we have expertise with. If successful, we believe we will have identified a foundational cellular strategy that will directly lead to a translatable approach in minimizing tissue injury during liver transplantation.